ReviewActa bio-medica : Atenei Parmensis2021
Biologic drugs in chronic spontaneous urticaria.
Review in Acta bio-medica : Atenei Parmensis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 4 citations in OpenAlex.
- Chronic Spontaneous Urticaria in the Era of Targeted Therapy: From Pathogenic Mechanisms to Precision Medicine.Pharmaceutics · 2026Review
- Healthcare Resource Utilization and Use of Biologics in Chronic Spontaneous Urticaria.The Journal of dermatology · 2026Article
- Lactobacillus paragasseri LG-1 Alleviates Urticaria-Like Symptoms in Mice via Modulation of Gut Microbiota, Hypoxanthine and Uric Acid.Microbial biotechnology · 2026Article
- Targeting type 2 inflammation in dermatology: mechanisms and clinical implications.Frontiers in immunology · 2026Review
- Factors Influencing Acceptance of Biologics and Small Molecule Targeted Drugs Among Patients with Chronic Spontaneous Urticaria: A Cross-Sectional Study.Patient preference and adherence · 2026Article
- Diagnosis of Tuberculosis in a Case of Chronic Urticaria following Omalizumab Therapy.Antibiotics (Basel, Switzerland) · 2023Article
- Current and Emerging Therapies for Chronic Spontaneous Urticaria: A Narrative Review.Dermatology and therapy · 2023Review
- Diagnosis and Management of Urticaria in Indian Settings: Skin Allergy Research Society's Guideline-2022.Indian journal of dermatologyArticle
- Resistant Chronic Spontaneous Urticaria - A Case Series Narrative Review of Treatment Options.Allergy & rhinology (Providence, R.I.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic spontaneous urticaria (CSU) is a condition defined by the presence of recurrent urticaria, angioedema, or both, which persist for more than six weeks in duration and occurs in the absence of an identifiable trigger. Both children and adults can develop CSU, although it is more common in adults and in women than in men, with a peak occurrence in the third to fifth decades of life. It imposes a significant burden on patients, families and healthcare systems. The goal of therapy in patients with CSU is to achieve a level of symptom control and improvement in quality of life that is acceptable to the patient, while minimizing therapy-related side effects. The recent introduction of biologic drugs has changed the management of the disease. This work aims to provide a narrative review of the current state of biological therapy and the promising drugs under development for CSU.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.